SCHEMBL2323909

SCHEMBL2323909

CCCCn1ncc(O)c(Cl)c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.41
KMT2A Q03164 3/20 0.41
ALDH1A1 P00352 6/20 0.40
HTT P42858 6/20 0.40
NPC1 O15118 4/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
MITF O75030 3/20 0.40
RAB9A P51151 5/20 0.39
POLB P06746 3/20 0.39
PAX8 Q06710 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
GPR55 Q9Y2T6 1/20 0.39
MAPT P10636 4/20 0.38
NPSR1 Q6W5P4 4/20 0.38
PKM P14618 1/20 0.38
LMNA P02545 2/20 0.37
RECQL P46063 1/20 0.37
TYR P14679 1/20 0.36
TSHR P16473 1/20 0.36
S1PR4 O95977 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9372838 0.85 HTT (0.38) GAAKMT2AALDH1A1HTTNPC1
SCHEMBL2361037 0.83 HTT (0.54) GAAKMT2AALDH1A1HTTNPC1
SCHEMBL9828927 0.83 GAA (0.57) GAAKMT2AALDH1A1HTTNPC1
SCHEMBL27692058 0.82 PKM (0.41) ALDH1A1NPSR1PKMLMNATYR
SCHEMBL10824672 0.81 KMT2A (0.41) GAAKMT2AALDH1A1HTTNPC1
SCHEMBL27691970 0.75 HTT (0.42) GAAKMT2AALDH1A1HTTNPC1
SCHEMBL2326495 0.75 HTR2A (0.41) GAAKMT2AALDH1A1HTTNPC1
SCHEMBL23401337 0.74 POLB (0.44) KMT2AALDH1A1HTTPOLBPKM
SCHEMBL19809108 0.73 TDP1 (0.39) ALDH1A1POLBNPSR1LMNATYR
SCHEMBL12160455 0.73 KAT2B (0.56) GAAALDH1A1RAB9AMAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210187131-A1 METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF LANTHEUS MEDICAL IMAGING, INC. (US) 2021-06-24 US disclosed
US-10842892-B2 Methods and apparatus for synthesizing imaging agents, and intermediates thereof LANTHEUS MEDICAL IMAGING, INC. (US) 2020-11-24 US disclosed
US-20190290788-A1 METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF LANTHEUS MEDICAL IMAGING, INC. (US) 2019-09-26 US disclosed
US-10022462-B2 Methods and apparatus for synthesizing imaging agents, and intermediates thereof LANTHEUS MEDICAL IMAGING, INC. (US) 2018-07-17 US disclosed
EP-3323810-A2 AUTOMATED REACTION SYSTEM, CASSETTE AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS Lantheus Medical Imaging, Inc. (US) 2018-05-23 EP disclosed
US-20170258947-A1 METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF LANTHEUS MEDICAL IMAGING, INC. (US) 2017-09-14 US disclosed
EP-2534136-B1 METHODS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF LANTHEUS MEDICAL IMAGING INC (US) 2017-09-06 EP disclosed
US-9603951-B2 Methods and apparatus for synthesizing imaging agents, and intermediates thereof LANTHEUS MEDICAL IMAGING, INC. (US) 2017-03-28 US disclosed
CN-102858752-A Method and apparatus for synthesizing imaging agents and intermediates thereof LANTHEUS MEDICAL IMAGING INC 2013-01-02 CN disclosed
WO-2011097649-A2 METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF LANTHEUS MEDICAL IMAGING, INC. (US) 2011-08-11 WO disclosed
EP-1713512-A4 CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING BRISTOL MYERS SQUIBB PHARMA CO (US) 2009-01-07 EP disclosed
EP-1713512-A2 CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING Bristol-Myers Squibb Pharma Company (US) 2006-10-25 EP disclosed
WO-2005079391-A2 CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2005-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190290788-A1 METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF TNNI3, FABP3, MPI GAA 846/4885KMT2A 4371/4885ALDH1A1 1208/4885
US-20210187131-A1 METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF TNNI3, FABP3, MPI GAA 846/4885KMT2A 4371/4885ALDH1A1 1208/4885
US-10022462-B2 Methods and apparatus for synthesizing imaging agents, and intermediates thereof TNNI3, FABP3, MPI GAA 846/4885KMT2A 4371/4885ALDH1A1 1208/4885
US-10842892-B2 Methods and apparatus for synthesizing imaging agents, and intermediates thereof TNNI3, FABP3, MPI GAA 846/4885KMT2A 4371/4885ALDH1A1 1208/4885
US-20170258947-A1 METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF TNNI3, FABP3, MPI GAA 846/4885KMT2A 4371/4885ALDH1A1 1208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.